Table 2.
Prevalence of HIV associated neurocognitive disorders
| Clinical stage
|
p value | Recruitment site
|
p value | Viral load (copies/ml)
|
p value | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| CDC-A (n=26) | CDC-B (n=52) | CDC-C (n=56) | Beijing (n=35) | Henan (n=56) | Yunnan 3 (n=43) | <50 (n=26) | > or =50 (n=108) | ||||
| ANI, n (%) | 4 (15.38) | 13 (25) | 13 (23.21) | NS | 10 (28.57) | 8 (14.29) | 12 (27.91) | NS | 5 (19.23) | 25 (23.15) | NS |
| MND, n (%) | 2 (7.69) | 5 (9.62) | 7 (12.5) | NS | 4 (11.43) | 6 (10.71) | 4 (9.3) | NS | 2 (7.69) | 14 (12.96) | NS |
| HAD, n (%) | 0 (0) | 2 (3.85) | 4 (7.14) | NS | 2 (5.71) | 1 (1.79) | 3 (6.98) | NS | 1 (3.85) | 3 (2.78) | NS |
| HAND, n (%) | 6 (23.08) | 20 (38.46) | 24 (42.86) | NS | 16 (45.71) | 15 (26.79) | 19 (44.19) | NS | 8 (30.77) | 42 (38.89) | NS |
CDC the Centers for Disease Control of the United States, ANI asymptomatic neurocognitive impairment, MND mild neurocognitive disorder, HAD HIV-associated dementia, HAND HIV associated neurocognitive disorders, NS non-significant at p<0.05